Targeting CDK4/6 in patients with cancer (Q26750703)

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

NFATc1 balances quiescence and proliferation of skin stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

A landscape of driver mutations in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

CDK6 levels regulate quiescence exit in human hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Cell cycle, CDKs and cancer: a changing paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Cyclin D as a therapeutic target in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Forging a signature of in vivo senescence

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Molecular pathways: CDK4 inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

CDK4: A Key Player in the Cell Cycle, Development, and Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Molecular genetics of familial cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Cyclin-dependent kinase pathways as targets for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2A (CDKN2A) in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

From cell cycle to differentiation: an expanding role for cdk6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CTRV.2016.03.002

7 January 2021

10.1016/J.CTRV.2016.03.002

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

27017286

1 reference

Consolidated OpenCitations Corpus – April 2017